WA
LGND icon

Wasatch Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Wasatch Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-312,901
Closed -$30.1M – 270
2021
Q4 		$30.1M Sell
312,901
-33,462
-10% -$3.09M 0.12% 144
2021
Q3 		$30.1M Buy
346,363
+2,572
+0.7% +$199K 0.12% 141
2021
Q2 		$28.1M Buy
343,791
+751
+0.2% +$62.5K 0.11% 155
2021
Q1 		$32.6M Sell
343,040
-1,530,862
-82% -$145M 0.15% 124
2020
Q4 		$116M Buy
1,873,902
+87,610
+5% +$4.99M 0.57% 65
2020
Q3 		$106M Buy
1,786,292
+229,101
+15% +$15.6M 0.68% 53
2020
Q2 		$109M Buy
1,557,191
+451,353
+41% +$28.6M 0.79% 44
2020
Q1 		$50.2M Buy
+1,105,838
New +$62.7M 0.52% 62

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Wasatch Advisors's LGND Position: Q1 2022 in Review

Wasatch Advisors sold out of Ligand Pharmaceuticals (LGND) in Q1 2022, closing a stake of 312,901 shares — an estimated $30.1M sold.

Wasatch Advisors first reported a position in LGND in Q1 2020 and held it in 8 quarters. The position peaked at $116M in Q4 2020. 208 funds tracked by Wall St. Rank hold LGND as of Q1 2022.

  • Wasatch Advisors reported no remaining Ligand Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Wasatch Advisors sold 312,901 Ligand Pharmaceuticals shares in Q1 2022, an estimated $30.1M.
  • Wasatch Advisors first reported a position in Ligand Pharmaceuticals in Q1 2020 and held it in 8 quarters.
  • Wasatch Advisors's Ligand Pharmaceuticals position peaked at $116M in Q4 2020.
  • 208 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2022.

Based on Wasatch Advisors's 13F filing for Q1 2022, filed 13 May 2022.